Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.

Fiche publication

Date publication

mars 2021

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe

Tous les auteurs :
Passildas-Jahanmohan J, Eymard JC, Pouget M, Kwiatkowski F, Van Praagh I, Savareux L, Atger M, Durando X, Abrial C, Richard D, Ginzac Couvé A, Thivat E, Monange B, Chollet P, Mahammedi H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33666378

Résumé

Metastatic castration-resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of curcumin with docetaxel could improve prognosis among mCRPC patients.